中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 8
Aug.  2016

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.08.018
  • Received Date: 2016-02-26
  • Published Date: 2016-08-20
  • Objective To investigate the clinical efficacy of 96- week entecavir( ETV) treatment for HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,as well as its effect on patients with different HBV DNA loads. Methods A total of 118 chronic hepatitis B patients with compensated cirrhosis who visited Xiangyang Hospital of Traditional Chinese Medicine from January 2009 to June 2013 were enrolled and all had Child- Pugh class A cirrhosis. According to HBV DNA load,these patients were divided into high- load group( group A,HBV DNA≥105copies / ml) and low- load group( group B,HBV DNA < 105 copies / ml). All the patients were treated with ETV 0. 5 mg / d for 96 weeks. Child- Pugh score was used to evaluate liver function before and after treatment,and the changes in alanine aminotransferase( ALT),albumin( Alb),and total bilirubin( TBil) after treatment were observed. Hyaluronic acid( HA),α2- macroglobulin,and liver stiffness measurement( LSM) were used to evaluate liver fibrosis. The t- test was used for comparison between groups,and a repeated- measures analysis of variance was used for comparison within one group and between groups at different time points. Chisquare test was applied for comparison of categorical data between the two groups. Results The two groups showed significant reductions in ALT,Alb,and TBil at weeks12 and 24 of treatment( all P < 0. 05),and the ALT normalization rate and HBV DNA clearance rate at weeks 24 and 48 of treatment showed significantly differences between the two groups( χ2= 9. 241,6. 428,11. 134,5. 139,all P < 0. 05). Both groups showed significant reductions in HA,α2- macroglobulin,and LSM after treatment( t = 2. 648,1. 921,4. 018,3. 166,2. 136,3. 461,all P < 0. 05). The incidence rates of complications such as variceal bleeding,ascites,and hepatocellular carcinoma showed no significant differences between the two groups( all P > 0.05). Conclusion In HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,ETV can significantly improve liver function,slow down the process of liver fibrosis and cirrhosis,and effectively reduce long- term complications.

     

  • [1]GAO YZ,JIA SH,ZHAO LF,et al.Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J].J Clin Hepatol,2014,30(4):314-316.(in Chinese)高远征,贾素华,赵连峰,等.恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察[J].临床肝胆病杂志,2014,30(4):314-316.
    [2]LOK A,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):1-36.
    [3]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
    [4]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement onthe management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(4):531-561.
    [5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
    [6]CHEN L,ZHOU XB,WEN DF,et al.Clinical features and liver pathology in chronic hepatitis B virus-infected patients with normal liver function[J].J Clin Hepatol,2015,31(9):1430-1433.(in Chinese)陈丽,周兴蓓,温丹凤,等.肝功能正常的慢性HBV感染者的临床特征及肝脏病理学分析[J].临床肝胆病杂志,2015,31(9):1430-1433.
    [7]HUANG YN,WU H.Progress in the antiviral treatment of HBVrelated cirrhosis[J].Fudan Univ J Med Sci,2013,40(2):233-238.(in Chinese)黄英男,吴昊.乙型肝炎肝硬化抗病毒治疗研究进展[J].复旦学报:医学版,2013,40(2):233-238.
    [8]WU Y,HAN L,YUAN YF,et al.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13,18.(in Chinese)吴岩,韩璐,原永芳,等.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13,18.
    [9]LIAW YF.Impact of therapy on the long term outcome of chronic hepatitis B[J].Clin Liver Dis,2013,17(3):413-423.
    [10]MARCELLIN P,ASSELAH T.Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal[J].J Gastroenterol Hepatol,2013,28(6):912-923.
    [11]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
    [12]ZHANG YX,ZHANG JB.Clinical efficacy of modified prescription of pingweisini combined with entecavir on patients at decompensation stage of liver cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition,2014,6(4):39-41.(in Chinese)张燕霞,张晋波.加减平胃四逆方联合恩替卡韦治疗乙型肝炎失代偿期肝硬化临床研究[J/CD].中国肝脏病杂志:电子版,2014,6(4):39-41.
    [13]KUMADA T,TOYODA H,TADA T,et al.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatol,2013,58(3):427-433.
    [14]CHANG ML,LIAW YF,HADZI YANNIS SJ.Systematic review:cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J].Aliment Pharmacol Ther,2015,42(3):243-257.
    [15]KIM YJ,HO HC,SINN DH,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.
  • Cited by

    Periodical cited type(16)

    1. 赵冰清,张国梁. 丹鸡活血汤结合穴位贴磁药治疗慢性乙型肝炎肝硬化临床疗效及安全性研究. 四川中医. 2021(07): 101-104 .
    2. 李静,毛重山,肖二辉,刘俊平,卢喜玲,彭真,刘翠平. 慢性乙型肝炎患者外周血单个核细胞中凋亡分子表达水平及临床意义. 华南预防医学. 2021(10): 1267-1271 .
    3. 肖松甲,肖闯,夏春炎. 恩替卡韦对肺结核合并乙肝病毒感染患者的疗效. 中国继续医学教育. 2020(02): 141-143 .
    4. 王立坤,霍丽亚,卢瑞杰,李哲. 恩替卡韦治疗代偿期肝硬化的效果及肝脏硬度值的影响. 医药论坛杂志. 2020(05): 116-119 .
    5. 王鹏,王波,南鹏,王丽. 恩替卡韦对代偿期乙肝肝硬化的治疗效果及对甲状腺激素的影响. 北方药学. 2019(04): 134-135 .
    6. 蔡丽娜,袁跃彬. 恩替卡韦治疗慢性乙型肝炎肝硬化失代偿期的疗效与安全性分析. 现代诊断与治疗. 2019(02): 250-252 .
    7. 郭强,赵科孝. HBeAg阴性慢性乙肝合并肝硬化患者血清HBV-DNA水平与肝功能的相关性. 海南医学. 2019(08): 973-976 .
    8. 王欣茹,咸建春. 注射用胸腺五肽联合恩替卡韦分散片治疗乙肝肝硬化肝功能代偿期的效果探讨. 中西医结合心血管病电子杂志. 2019(17): 28-29 .
    9. 杨树峰. 治疗慢性乙型肝炎采用恩替卡韦治疗的临床效果分析. 世界最新医学信息文摘. 2019(A2): 102-103 .
    10. 胡勇平,骆晓霞,李园英,黄晓宁,谢勇辉,孔小清. 白细胞介素2联合恩替卡韦初始治疗重症慢性乙型肝炎的疗效观察. 中国医院用药评价与分析. 2018(06): 748-750 .
    11. 张晓旭,娄宪芝. 胸腺肽ɑ1注射剂联合恩替卡韦胶囊治疗肝硬化肝功能代偿期的临床研究. 中国现代医药杂志. 2018(08): 49-50 .
    12. 陈晨楠. 恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的临床效果观察. 现代医学与健康研究电子杂志. 2018(14): 38 .
    13. 黄玉华. 对慢性肝炎肝硬化患者进行人文关怀护理的效果分析. 当代医药论丛. 2017(18): 213-214 .
    14. 李亚萍. α-干扰素联合恩替卡韦治疗慢性乙型肝炎的临床效果观察. 临床和实验医学杂志. 2017(12): 1190-1192 .
    15. 潘泓多,任丽梅. 恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的效果分析. 世界最新医学信息文摘. 2017(71): 40 .
    16. 王树霞. 恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的可行性研究. 现代医学与健康研究电子杂志. 2017(08): 59 .

    Other cited types(0)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2469) PDF downloads(463) Cited by(16)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return